Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multicenter, Open-label, Phase 2 Study to Evaluate the Efficacy and Safety of SKB264 Monotherapy in Selected Subjects With Advanced Solid Tumors

NCT05631262 is registered in ClinicalTrials.gov with Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. as lead sponsor.

NCT NCT05631262
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05631262 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multicenter, Open-label, Phase 2 Study to Evaluate the Efficacy and Safety of SKB264 Monotherapy in Selected Subjects With Advanced Solid Tumors
Lead sponsor
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.
Phase
Phase 2
Overall status
Active, not recruiting
Start date
November 30, 2022
Completion date
December 30, 2026
Enrollment
321 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

selected subjects with advanced solid tumors